<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602588</url>
  </required_header>
  <id_info>
    <org_study_id>UCL11/0404</org_study_id>
    <nct_id>NCT01602588</nct_id>
  </id_info>
  <brief_title>A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)</brief_title>
  <acronym>HCQ</acronym>
  <official_title>A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is emerging evidence that hydroxychloroquine (HCQ), a drug used commonly in the
      prevention/ treatment of malaria, rheumatoid arthritis and lupus erythematosus, may improve
      survival outcome in a variety of cancers including HGG, with few side effects.

      In this trial the investigators wish to investigate whether treatment with radiotherapy and
      hydroxychloroquine is more effective than treatment with radiotherapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year Survival</measure>
    <time_frame>The survival rate will be calculated by the number of patients alive 1 year after entering the trial.</time_frame>
    <description>The primary endpoint of the trial is survival at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Toxicity will be assessed during and up to 30 days after treatment</time_frame>
    <description>Adverse Events will be collected for all patients in the trial during treatment and up to 30 days afterwards.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: SCRT alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200mg bd from 14 days post surgery until clinical or radiological progression</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>HCQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Short Course radiotherapy</description>
    <arm_group_label>Arm A: SCRT alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged ≥70 yrs identified through the neurooncology MDT.

          -  A histological diagnosis of HGG, either from biopsy or resection.

          -  A life expectancy of &gt; 2 months

          -  An ECOG performance status of 0/1

          -  Absolute neutrophil count ≥ 1.5 x 109

          -  Platelet count ≥ 100 x 109

          -  Bilirubin ≤ 1.5 mg/dL (or ≤ 25.6 µmol/L)

          -  Creatinine ≤ 2 times upper limit of normal (ULN)

          -  ALT and AST ≤ 4 times ULN

          -  Mini Mental Status Exam score ≥ 17 (Appendix 10)

          -  Written informed consent

          -  Ready to start radiotherapy within 4 weeks of surgery

        Exclusion Criteria:

          -  Concurrent psoriasis unless the disease is well controlled and patient is under the
             care of a specialist for the disorder who agrees to monitor for exacerbations

          -  Prior macular degeneration or diabetic retinopathy

          -  Concurrent serious infection or medical illness that would preclude study therapy

          -  Another malignancy within the past 5 years except for curatively treated carcinoma in
             situ or basal cell carcinoma of the skin

          -  Porphyria

          -  Glucose- 6 phosphate dehydrogenase (G6PD) deficiency

          -  Alcoholic liver disease

          -  Any other concurrent severe/uncontrolled medical conditions

          -  Currently taking amiodarone

          -  Prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins,
             immunoconjugates, antisense agents, peptide receptor antagonists, interferons,
             interleukins, tumour-infiltrating lymphocytes, lymphokine-activated killer cell
             therapy, or gene therapy), or hormonal therapy for brain tumour

          -  Prior polifeprosan 20 with carmustine implant (Gliadel wafer) or GliaSite®
             brachytherapy

          -  Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin,
             carbamazepine, phenobarbital, primidone, or oxcarbazepine)

          -  Other concurrent chemotherapeutic or investigational agents for this cancer
             (Concurrent glucocorticoids will be allowed

          -  Documented side effects to chloroquine or related agents.

          -  Unable to give informed consent

          -  Patients with a history of a psychological illness or condition that in the opinion of
             the investigator may adversely affect compliance with study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Short, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>St James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Bodelwyddan</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas's Hospitals</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>w6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospitals</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

